ASPG and acute lymphoblastic leukemia: COG AALL1931 (NCT04145531) is an ongoing phase 2/3 study of Rylaze in patients with ALL/LBL who developed hypersensitivity or silent inactivation to a long-acting E. coli–derived asparaginase.